Cartesian Therapeutics, Inc. Proceeds from Lines of Credit
Cartesian Therapeutics, Inc. (RNAC) reported Proceeds from Lines of Credit of $0 for the 12-month period ending 2019-12-31, per its 10-K filed 2020-03-12.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromLinesOfCredit · last filed 2020-03-12
- Cartesian Therapeutics, Inc. proceeds from lines of credit for the quarter ending 2018-12-31 was $0.00.
- Cartesian Therapeutics, Inc. proceeds from lines of credit for the quarter ending 2017-12-31 was -$42.00K.
- Cartesian Therapeutics, Inc. proceeds from lines of credit for the quarter ending 2016-12-31 was $0.00.
- Cartesian Therapeutics, Inc. proceeds from lines of credit for fiscal 2019 was $0.00.
- Cartesian Therapeutics, Inc. proceeds from lines of credit for fiscal 2018 was $0.00, a 100.00% decline from fiscal 2017.
- Cartesian Therapeutics, Inc. proceeds from lines of credit for fiscal 2017 was $20.96M.
- Cartesian Therapeutics, Inc. proceeds from lines of credit for fiscal 2016 was $0.00, a 100.00% decline from fiscal 2015.
| Period end | Proceeds from Lines of Credit 3 month | Proceeds from Lines of Credit 9 month | Proceeds from Lines of Credit 12 month |
|---|---|---|---|
| 2019-12-31 | $0.00 10-K · filed 2020-03-12 | ||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $0.00 10-K · filed 2020-03-12 | |
| 2018-09-30 | $0.00 10-Q · filed 2018-11-08 | ||
| 2017-12-31 | -$42.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $20.96M 10-K · filed 2020-03-12 | |
| 2017-09-30 | $21.00M 10-Q · filed 2018-11-08 | ||
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-15 | $0.00 10-K · filed 2019-03-15 | |
| 2016-09-30 | $0.00 10-Q · filed 2017-11-07 | ||
| 2015-12-31 | $6.67M 10-K · filed 2018-03-15 | ||
| 2014-12-31 | $4.49M 10-K · filed 2017-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |